How do drugs work?
The main goal of pharmacology is to create easy-to-take medications with maximum effectiveness and minimal side effects. The ideal option is a medicine that acts locally and does not affect the rest of the body. To achieve this, different forms of drug release are needed in different cases.
To determine the correct functioning of a drug in pharmacology, there are two concepts: bioavailability and half-life.
Bioavailability is the amount of a substance that reaches its intended purpose. This process is hampered by the body's protective barriers. The selection of the dose for treatment and the method of administration depend on bioavailability.
The half-life is the time after which the level of the drug is reduced to half its original level and ceases to have an active effect on the body. It is this period that determines how many times a day you need to take the medicine.
Ketorol
NSAIDs have a pronounced analgesic effect, have anti-inflammatory and moderate antipyretic effects. The mechanism of action is associated with non-selective inhibition of COX activity (COX-1 and COX-2), which catalyzes the formation of prostaglandins from arachidonic acid, which play an important role in the pathogenesis of pain, inflammation and fever. Ketorolac is a racemic mixture of [-]S- and [+]R-enantiomers, with the analgesic effect due to the [-]S-form. The strength of the analgesic effect is comparable to morphine, significantly superior to other NSAIDs.
The drug does not affect opioid receptors, does not depress respiration, does not cause drug dependence, and does not have a sedative or anxiolytic effect.
After oral administration, the analgesic effect develops within 1 hour.
Pharmacokinetics
Suction
When taken orally, ketorolac is well and quickly absorbed from the gastrointestinal tract. The bioavailability of ketorolac is 80-100%, Cmax after oral administration at a dose of 10 mg is 0.82-1.46 mcg/ml, Tmax is 10-78 minutes. Food rich in fat reduces the Cmax of the drug in the blood and delays its achievement by an hour.
Distribution
Plasma protein binding is 99%, Vd is 0.15-0.33 l/kg. The time to reach Css when taken orally at a dose of 10 mg 4 times a day is 24 hours, Css is 0.39-0.79 mcg/ml.
Excreted in breast milk: when taking ketorolac at a dose of 10 mg, Cmax in breast milk is achieved 2 hours after taking the first dose and is 7.3 ng/ml, 2 hours after taking the second dose of ketorolac (when using the drug 4 times a day) – 7.9 ng/l.
Metabolism
More than 50% of the administered dose is metabolized in the liver with the formation of pharmacologically inactive metabolites. The main metabolites are glucuronides and p-hydroxyketorolac.
Removal
Excreted mainly by the kidneys - 91%, through the intestines - 6%, glucuronides are excreted in the urine. Not excreted by hemodialysis.
T1/2 in patients with normal renal function averages 5.3 hours (2.4-9 hours after oral administration at a dose of 10 mg). When administered orally at a dose of 10 mg, the total clearance is 0.025 l/h/kg.
Pharmacokinetics in special groups of patients
T1/2 increases in elderly patients and shortens in young ones.
Impaired liver function does not affect T1/2.
In patients with renal failure, the Vd of the drug may increase by 2 times, and the Vd of its R-enantiomer by 20%. In patients with impaired renal function with a plasma creatinine concentration of 19-50 mg/l (168-442 µmol/l), T1/2 is 10.3-10.8 hours, with severe renal failure - more than 13.6 hours. In patients with renal failure (with plasma creatinine concentrations are 19-50 mg/l) total clearance is 0.016 l/h/kg.
Why are the shapes different?
Initially, there were only two ways to deliver medicine to the body: swallowed or applied; other options were not available to doctors of the past.
But with the development of medicine, it has become clear that these options do not always work. When swallowed, the drug has a long journey to travel. Before getting to the right place, the tablet passes through the aggressive environment of the stomach. And after absorption, the substances enter the liver through the bloodstream, where toxins are neutralized and the medicine can become inactive before reaching the target organ.
Also, some drugs can negatively affect the functioning of the gastrointestinal tract. Cause nausea, vomiting or simply not work if the stomach or intestines are not in order and absorption is impaired.
“A classic example is when we changed a patient’s drug,” says GMS Clinic therapist Andrey Besedin, “during exacerbations of gastric ulcer, duodenal ulcer, or after surgery on the gastrointestinal tract. In this case, it is better to choose intramuscular or intravenous administration."
There are situations when it is necessary to administer medications intravenously. Most often this is due to urgency, but there are drugs that are destroyed in the gastrointestinal tract. For example, some antibiotics are available only in the form of injections, and in this case injections cannot be avoided.
“Any intramuscular, subcutaneous, intravenous injection is a small operation,” explains Andrey Besedin, “during which we violate the integrity of the body, skin, muscles, depending on what we do. Therefore, if possible, it is better to use tablets and capsules.”
There are medications that have serious effects on the entire body when taken in the form of tablets or injections. For such cases, local forms were invented. Thus, hormones in creams and nasal spray are useful for skin manifestations and allergic rhinitis, but the same hormones in large doses can cause serious consequences with long-term use of tablets or intravenous injections.
For children, medications are available in the form of chewable tablets, drops, or reduced-size tablets, so as not to turn every dose of medication into a battle or cause the association between treatment and pain. Unfortunately, this is not always possible, especially in children's hospitals.
“There are no unambiguous dogmas in medicine,” says Andrey Besedin, “in each situation we choose the type of drug administration individually, depending on what goals we want to achieve with a particular patient.”
Non-steroidal anti-inflammatory drug Ketorol in the treatment of pain syndromes
A drug with a mechanism of action that suppresses the activity of both forms of COX (COX-1 and COX-2) is ketorolac (international nonproprietary name), trade name Ketorol® (Dr. REDDY'S Laboratoris Ltd.). The active substance of the drug is ketorolac tromethamine [3, 4], which is a racemic mixture of (-)S- and (+)R-enantiomers, and the analgesic effect is due to the (-)S-form. The drug is rapidly absorbed, has high bioavailability (80–100%), binds to plasma proteins by 90–99%, undergoes hepatic metabolism, and is excreted by the kidneys (90%) and intestines (6%). After oral administration of 10 mg, the effect develops after 10–60 minutes, after intramuscular administration of 30 mg - after 15 minutes. The duration of action of the drug is 6–10 hours. However, due to the high risk of complications typical of NSAIDs, the period of its recommended use is limited to 5 days. In this mode, as studies have shown, the intensity of pain syndrome is reduced by 66% by the 3rd day of treatment, and by 82% by the 5th day [1, 5]. The therapeutic potential of ketorolac has been proven for all areas of urgent analgesia; in monotherapy, its effect is comparable to small doses of “hard” opioids [6]. In terms of analgesia, it is superior to other NSAIDs and is among the first-line drugs for short-term treatment of severe pain [7, 8]. The drug does not act on opioid receptors, therefore it does not cause adverse reactions from the central nervous system, respiratory depression and smooth muscle paresis, drug dependence, and does not have a sedative or anxiolytic effect [3, 4]. The significant analgesic effect of ketorolac is emphasized, comparable to the effect of narcotic analgesics [9], with a significantly lower incidence of serious adverse drug reactions, which together significantly reduces the cost of pharmacotherapy. Release forms: 1) tablets for oral administration of 10 mg, 2) solution for parenteral administration in ampoules of 30 mg / 1 ml, 3) 2% Ketorol gel for topical use (contains 20 mg of active substance). Indication for use is pain of severe and moderate severity (intended for symptomatic therapy, reducing the intensity of pain and inflammation at the time of use; does not affect the progression of the disease) of various origins and localization: trauma, toothache, pain in the postpartum and postoperative period, pain syndrome for oncological diseases, myalgia, arthralgia, neuralgia, radiculitis, dislocations, sprains, rheumatic diseases. When applied topically, Ketorol gel causes a weakening or disappearance of pain at the site of its application, incl. pain in the joints at rest and during movement, reduces morning stiffness and swelling of the joints [3, 4]. The drug Ketorol gel should be prescribed with caution to elderly people and pregnant women (I and II trimesters). Studies on the use of ketorolac in urgent conditions The results of a prospective multicenter study conducted in 49 clinics in 8 European countries showed [10] that ketorolac is highly effective in relieving acute pain syndromes after surgery (orthopedic, abdominal, gynecological, urological, plastic surgery) . A comparative analysis of the effectiveness and safety of ketorolac with diclofenac and ketoprofen included the results of treatment of 11,245 patients. It was found that the incidence of adverse drug reactions when taking ketorolac (90 mg/day for 2 days parenterally, then 40 mg/day for 7 days) did not differ in comparison with that when using diclofenac (150 mg/day for 2 days parenterally, then 150 mg/day for 7 days). mg/day for 7 days) or ketoprofen (200 mg/day for 2 days parenterally, then 200 mg/day for 7 days). At the same time, the risk of developing gastrointestinal bleeding and allergic reactions was significantly lower in patients taking ketorolac compared to the comparison group (diclofenac, ketoprofen). The Department of Surgery at the University of British Columbia Hospital (Vancouver, Canada) conducted a multicenter, double-blind, randomized study to compare the rate and extent of the onset of analgesic effect and the patient's functional status with a single IV dose of ketorolac and dose titration of meperidine, as well as the occurrence of adverse events [11] . This study looked at patients aged 18–65 years with moderate to severe renal colic. They were divided into 2 groups, comparable by gender and age, race and other parameters. Patients in the meperidine group received 50 mg IV at time zero, then 25–50 mg every 15 minutes. to relieve ongoing pain. Patients in the ketorolac group received 30 mg IV at time zero and placebo injections every 15 minutes. as needed. The level of pain and adverse events were assessed every 15 minutes, functional status - after 60 minutes. The main criterion for the effectiveness of the drug was the reduction of pain to moderate or its disappearance after 60 minutes. Adequate pain relief was experienced by 72% of patients receiving ketorolac and 64% of patients receiving meperidine; 44% of patients receiving ketorolac and 10% of patients receiving meperidine were able to resume normal activities after 60 minutes. The authors concluded that single IV administration of ketorolac at study doses for the relief of acute renal colic is equally effective as IV titration of meperidine and causes less functional impairment. Thus, ketorolac has been shown to be an effective drug for the treatment of renal colic, does not require close patient monitoring and does not cause adverse sedation. A comparative study conducted at the Department of Head and Neck Surgery at Loyola University Hospital (Maywood, USA) [12] assessed the efficacy and safety (risk of bleeding) of intravenous ketorolac 30 mg postoperatively in patients undergoing primary endoscopic surgery. paranasal sinuses (septum surgery), compared with the effectiveness and safety of 25 mcg fentanyl. The level of postoperative pain was recorded at 0, 30 and 60 minutes. on a visual analogue scale (VAS). Patients received fentanyl and hydrocodone/acetaminophen as needed (if pain was not sufficiently relieved). Questionnaires assessing postoperative bleeding were completed on the 1st and 7th postoperative days. 34 patients were observed, of which 16 received IV ketorolac, 18 received fentanyl. There were no significant differences in the groups when assessing pre- and postoperative hemoglobin levels, the appearance of bleeding, the severity of pain according to VAS, or the number of doses of additional analgesics. Thus, ketorolac administered intravenously was a safe analgesic during endoscopic surgery of the paranasal sinuses, because There was no increased risk of bleeding or acute posthemorrhagic anemia. The analgesic effect of IV administration of ketorolac is comparable to the effect of IV administration of fentanyl. Another study, conducted in the Department of Urology at Howard University Hospital (Washington, USA), assessed the degree of analgesic effect of 60 mg ketorolac administered intravenously during outpatient transrectal ultrasound examination and prostate biopsy [13]. The prospective study involved 24 patients who were randomized into 2 groups: Group 1 received 60 mg of ketorolac intravenously before the procedure, Group 2 (control) received no anesthesia. The number of biopsies performed, in which patients were able to withstand the entire procedure, was significantly lower in the control group than in the group that received IV ketorolac. In contrast, pain levels in patients receiving IV ketorolac were significantly lower than in patients without pain relief. Thus, intravenous administration of ketorolac significantly reduces pain during a painful procedure in full and allows patients to tolerate it more easily. Application of Ketorol in dental surgery E.A. Bazikian et al. (2005) conducted a comparative study to evaluate the effectiveness of the drug Ketorol in relieving pain in 30 patients (15–59 years) [14]. To relieve pain, Ketorol was prescribed 30 minutes in advance. before surgery IM in a single dose of 30 mg. In the following days (if necessary), Ketorol was prescribed per os at a dose of 10 mg. The daily dose did not exceed 40 mg. The total duration of use of Ketorol was determined by the need to relieve pain by the patients themselves and did not exceed 2 days (in patients undergoing implantation, Ketorol was used once 30 minutes before surgery). Thus, the studies have shown that Ketorol provides fairly reliable and adequate pain relief in the postoperative period. The authors concluded that Ketorol is safe when prescribed for prophylactic purposes (i.e., before pain syndrome), promoting a painless course of the postoperative period, and recommend including it as a permanent component of premedication. O.A. Egorova (2009) conducted a study to evaluate the effectiveness of Ketorol in relieving pain after dental surgery in outpatient practice [15]. The study included 40 patients (19–50 years old) who were treated in a dental surgery office. The first dose of Ketorol (10 mg) was immediately after surgery (against the background of the action of the anesthetic). The maximum intensity of the pain syndrome was recorded 1–2 hours after the operation; no increase in the intensity of the pain syndrome was observed while taking Ketorol. In case of pain syndrome, patients were recommended to continue taking Ketorol at a dose of 10 mg, but not more than 40 mg/day. The average daily dose of the drug was 20 mg. The course of taking Ketorol among those observed did not exceed 2 days. Thus, this study demonstrated the effectiveness of Ketorol as a powerful analgesic during a short course of use in patients after dental surgery and demonstrated its safety. A.A. Timofeev et al. (2012) provided a comparative description of non-narcotic analgesics – ketorolac and dexketoprofen, used in maxillofacial surgery for postoperative pain relief for patients [6]. 155 patients were examined: Group I (n=72) – after maxillofacial surgical interventions (removal of osteoblastomas and jaw cysts); Group II (n=40) – with open fractures of the body of the lower jaw; Group III (n=43) – with inflammatory diseases of the soft tissues of the maxillofacial region and neck (abscesses and phlegmon in patients with drug addiction). On the 1st day after surgery, ketorolac was prescribed intramuscularly at 10–20 mg every 8 hours (3 times a day), on the 2nd–3rd day – 10–20 mg every 12 hours (2 times a day). ), and on days 4–5 – 10 mg 2 times a day. On the 1st day after the operation, in patients of group I (n=27), severe pain (6–7 points) was observed in 46.8% of cases, moderate pain (4–5 points) – in 53.2%; on the 5th day, postoperative pain of low intensity was noted in 42.6%, pain was absent in 57.4% of cases. In group II, ketorolac was prescribed (n=20) according to the following regimen: in the first 2 days – 10–20 mg p/o or intramuscularly every 8 hours (3 times/day), on days 3–5 – p/o o 10 mg every 12 hours (2 times/day). After 30–45 min. after the first dose, a significant decrease in pain response was observed. In group III, ketorolac was prescribed (n=22) according to the following regimen: in the first 2–3 days of treatment intramuscularly, from the 3rd–4th day - po, on the 4th day after opening the purulent-inflammatory focus no pain was noted . Patients taking ketorolac had a more pronounced and prolonged analgesic effect compared to dexketoprofen, and the least number of side effects. Thus, ketorolac can be recommended for use in the postoperative period after removal of tumor-like and tumor formations of the jaws, for fractures of the lower jaw, after opening abscesses and phlegmons in patients burdened with drug addiction [6]. Ketorolac in the treatment of diseases of the musculoskeletal system The main goal of the treatment of acute nonspecific pain in the lumbosacral spine is, first of all, pain relief. Therapy is focused on drugs from the NSAID group with the most effective risk/benefit ratio, of which the sequential use of Ketorol and Nise currently deserves special attention. A pain relief regimen was proposed: if necessary, prolong therapy, switching to Nise 200 mg/day, 7–10 days is possible (Fig. 1) [1]. E.A. Galushko et al. (2008) conducted an open, controlled, randomized comparative study with similar forms of diclofenac sodium [16]. An assessment was made of the clinical effectiveness and tolerability of 2 dosage forms of Ketorol (tablets and solution for injection) in patients with osteoarthritis (OA) of the knee joint with severe pain. The study included 109 patients: the main group consisted of 51 patients with gonarthrosis, of which 25 received the tablet form of Ketorol (10 mg 2 times a day), 26 received the injection form (1 ml - 30 mg once); The control group consisted of 58 patients who received diclofenac (50 mg 2 times a day or 3 ml - 75 mg once). An assessment of the short-term effectiveness of the therapy showed that Ketorol is not only not inferior to diclofenac in the effectiveness of pain suppression in OA, but also exceeds it in the severity of pain relief by 25–30%. Good effectiveness (according to doctors) was noted already in the first 3 days of using Ketorol and was detected in more than half of the patients, while when using diclofenac - in 17% of those receiving tablets and in 36% of those receiving injections. In 9.8% of cases, adverse events were noted: dyspepsia and epigastric pain, and in 1.9% - an allergic reaction. To assess the safety of the drug, the levels of liver enzymes (ALT, AST), creatinine and hemoglobin in the blood were determined in all patients. The indicators were assessed during the initial examination and 5 days after starting Ketorol. The levels of the above laboratory parameters did not change significantly and remained normal throughout the study, which indirectly indicates the absence of side effects of the drug on kidney, liver and blood function. The presented results indicate the high analgesic effectiveness of Ketorol for gonarthrosis [16]. According to data provided by A. Garkavi et al. (2009), when relieving acute pain syndrome in patients with pathology of the musculoskeletal system in the early post-traumatic and postoperative periods, the effectiveness of Ketorol on the 1st day is not inferior to the effectiveness of tramadol, which is accompanied by fewer side effects [17]. ON THE. Szostak et al. (2006) provide data that the administration of Ketorol to patients with various pathologies in the clinic of internal medicine made it possible to completely relieve pain in 20% of patients, significantly reduce the severity of pain in 55% and reduce the severity of pain in 25% [5] . Based on the data obtained, the authors classified Ketorol as one of the effective and safe drugs used in the complex treatment of diseases of internal organs (pleuropneumonia, chronic non-calculous cholecystitis, urolithiasis, etc.) complicated by pain. According to the data given in the article by V.V. Skvortsova et al. (2011), after intramuscular administration of ketorolac, the maximum concentration in the blood plasma is achieved after 15–60 minutes. [18]. The drug is administered in a dose of 10–30 mg every 4–6 hours, depending on the severity of the pain syndrome. Ketorolac should be prescribed at the minimum effective dose. The maximum daily dose for adult patients under 65 years of age should not exceed 90 mg, for patients over 65 years of age or with impaired renal function - 60 mg. The maximum duration of parenteral use of the drug is 5 days. When transferring a patient from parenteral administration to oral administration, the total daily dose of ketorolac in both dosage forms on the day of transfer should not exceed 90 mg for patients under 65 years of age and 60 mg for patients over 65 years of age or with impaired renal function. In this case, the dose of the drug in tablets on the day of transition should not be more than 30 mg. Orally, 10 mg is prescribed every 4–6 hours (no more than 4 tablets/day, the maximum daily dose should not exceed 40 mg). Ketorolac in the outpatient practice of G.I. Bragina et al. (2006) in outpatient practice studied the effectiveness and safety of Ketorol in patients with acute pain syndrome of various origins [19]. The study was conducted in clinics No. 37, 56, 102 of the Moscow Department of Health and in clinic No. 3 of the Central Clinical Hospital of the Russian Academy of Sciences. 95 patients were observed (mean age: 54.6±10.6 years). The pain syndrome in patients was caused by arthropathy, dorsopathies, spondylopathy, soft tissue lesions, injuries of the musculoskeletal system, etc. In 36% of patients, preceding therapy with analgesics or NSAIDs, the effect of which was absent or insignificant. Patients were divided into 2 groups: I group (n = 52) received ketorol, II group (n = 43) - ketoprofen. The duration of therapy was 5 days. A comparative assessment of the intensity of pain according to your (0–100) against the background of taking drugs: before treatment, after 15, 30 minutes, 2, 6 hours. During the study, a change in the intensity of pain against the background of ketorol intake was obtained - 83.8 ± 11, 6 points (before treatment) VS 39.8 ± 20.8 points (after 6 hours), ketoprofen - 81.0 ± 10.8 points (before treatment) VS 46.7 ± 14.0 points (after 6 hours). Over the next 5 days, the regression of the pain syndrome was noted, and when using ketorol, a positive effect is achieved with a dynamically decreasing daily dose of the drug substance. When taking ketorol in 7.5% of cases, undesirable side effects were noted: discomfort and pain in the epigastric region, dizziness, difficulty in urination. Thus, the clinical efficiency and safety of ketorol in a dosage of 30 mg/day were demonstrated in the treatment of patients with acute pain for 5 days, which allows us to recommend this drug for wide use in outpatiental-linenic practice in patients with acute pain syndrome [19] . In the study by A.L. Vertkina et al. (2004) Assessment of comparative painkillers and safety of ketorolac and metamizole sodium in pain at the prehospital stage [20]. The study included 445 patients (the average age - 51 ± 4.9 years), which were divided into 2 groups: Ketorolak group (n = 220) and a group of sodium metamizole (n = 225). The severity of the pain syndrome is estimated by your (0–100), and patients also noted the level of pain intensity in 20 minutes. After a single in/m introduction of ketorolac at a dose of 30 mg. In the course of the study, the following results were obtained: 1) the analgesic efficiency of ketorolac (according to yours) is 2.6 times higher than that of the sodium metamizole; 2) the pain completely disappeared in 12.7% of cases after taking ketorolac and only in 2% after taking sodium metamizole; 3) the introduction of ketorolak was effective in all cases, in the group of metamizole sodium in 5.3% there was no effect. The frequency of development of side effects (most often dyspeptic symptoms) when using ketorolac was 2.7%. Thus, ketorolac provides high efficiency, rapid and prolonged anesthesia, and low risk of side effects. Not being an accounting drug, ketorolax can be recommended for use as an analgesic of the first row at the prehospital stage in an ambulance [20]. A.L. Vertkin et al. (2006), as part of the program of the National Scientific and Practical Society for the Emergency Medical Assistance, the first comparative open multicenter controlled clinical study of the efficiency and safety of the parenteral use at the pre-capital stage of NSAIDs (sodium, sodium diclofenac, ketorolac and loroxicam) was carried out with various origin of various origin [7 , 8]. The study included 1011 patients (average age - 54.1 ± 0.46 years). At the prehospital stage, they introduced a 2 ml of a 50% solution of in/m of metamizol sodium (n = 240), 3 ml - 75 mg of V/m of diclofenac (n = 153), or 30 mg/1 ml in/m ketorolac (n = 318 ), or 8 mg/2 ml in/m loroxicam (n = 95). From the study, 54.7% took part in urgent help in connection with skeletal-muscular pain, 24.1% for injury, 21.2% with renal colic. According to the criteria, your better efficiency was possessed by Loroxics and ketorolac, according to the results of the assessment of the dynamics of pain, ketorolalacts surpasses sodium metamizol by 1.3 times. In the course of the study, it was revealed: 1) by the number of repeated calls, the drugs are located as follows: metamizole> diclofenac> ketorolala = Loroxes; 2. min.; 3) according to the speed of the onset of a distinct painkillers, the drugs were distributed as follows: Loroxics = Ketorolak> Diclofenac> Metamizole; 4) by the strength of analgesic effect on injury, the studied drugs can be arranged as follows: ketorolala> Loroxics> Diclofenac = metamizole. The average difference in the intensity of the pain that occurred in connection with the injury before and after treatment for yours in the Metamizole group was 58.9 ± 3.0 points, diclofenac - 60.0 ± 4.6 points, ketorolac - 77.8 ± 1.9 score, loroxicam - 68.0 ± 4.7 points. According to this indicator, Ketorolakus was superior in analgesic activity to the Loroxes and the rest of the analgesics. Among the unwanted phenomena when using ketorolac in 9.4% of cases, dyspepsia was noted, in 2.9% - urticaria. Thus, the presented results indicate the feasibility of using ketorolac at the prehospital stage of the treatment of acute pain, while this drug is the most effective in injury and acute skeletal-muscle pain in comparison with other analgesics and NSAIDs [7, 8]. A.L. Vertkin et al. (2011) Assessment of the effectiveness and safety of the use of NSAIDs to stop the pain syndrome in the practice of the doctor on duty in a multidisciplinary hospital [21]. The study included 627 patients (average age - 56.7 ± 6.3 years) with pain syndrome, which were in a stationary treatment in a multidisciplinary hospital (compartment of therapy, general surgery, neurology) of ambulance). A metamizole of sodium + pythofenon + Fenpianius bromide at a dose of 5.0 ml iv, diclofenac - 75 mg iv, ketorolax - 10 mg iv, paracetamol - 500 mg iv droppings was prescribed. In assessing the effectiveness of reducing ketorolac pain, it turned out to be the most effective in patients in therapeutic departments, surgical practice. Assessing the analgesic potential of drugs in all departments, the authors note the greatest effectiveness of ketorolac. The most rapidly anesthetic effect was felt by the patients who were prescribed by ketorolac (48.7 minutes). After 12 hours, patients evaluated the quality of anesthesia on a 5-point scale and O-the average score 4.6. Thus, it is concluded that by the subjective assessment of the effectiveness of pain relief in your best drug for emergency anesthesia, ketorolac is. In terms of efficiency/safety ratio, the advantage in choosing pain relief in the practice of the doctor on duty of a multidisciplinary hospital also in ketorolac. In addition, the adequate relief of the painful syndrome is an important additional factor in the stabilization of blood pressure in patients with a hypertensive crisis [21]. The use of ketorolac in the treatment of cervicogenic headaches Effective therapy of cervicogenic headaches (CGB) is possible with a complex approach and joint use of pharmacological and non -drug methods, including blockades with local anesthetics. Medical blockades with local anesthetics temporarily reduce the intensity of pain and reliably increase the effect of drug therapy. In the treatment of CGB, drugs of various groups are used: NSAIDs, muscle relaxants, antidepressants, anticonvulsants [22]. At the same time, according to most experts, it is more preferable to use NSAIDs (ketorolak, diclofenac, nimesulide). The use of NSAIDs is possible both for stopping acute pain and as part of complex therapy for chronic CGB. It is advisable to prescribe drugs with a pronounced anti -inflammatory and analgesic effect, given the accompanying somatic pathology. In neurological practice, the use of Ketorolak is recommended in the treatment of the Central City Hospital for no more than 5 days in the form of in/m injections at a dose of up to 90 mg/day or in a tablet form of 20–40 mg/day [22]. The conclusion of the studies demonstrated the clinical efficiency and safety of the drug ketorolac in the form of in/m injections at a dose of up to 90 mg/day or in a tablet form of 20–40 mg/day (an average of 30 mg/day) for no more than 5 days in treatment Patients with acute pain syndrome [23]. According to the instructions for the new form of use of the drug, Ketorol Gel is applied 3-4 r/day (no more), the duration of use is up to 10 days [4]. The analgesic activity of Ketorolak exceeds such analgesics. The safety of the drug is confirmed on the basis of laboratory tests. Thus, the need for the widespread use of ketorolac (ketorola) in outpatient and voglinical practice is shown in patients with acute pain, at the prehospital stage in an ambulance as an analgesic of the first row, in the provision of ambulance, in the provision of ambulance with urgent conditions.
Literature 1. Alekseev V.V. Stepped NSAID therapy for acute pain in the lumbosacral region // Effective pharmacotherapy in neurology and psychiatry. 2010. No. 4. pp. 22–28. 2. Erokhin A.I., Voronkova V.V., Kuzin A.V. The effectiveness of Ketorol for pain syndrome at an outpatient dental appointment. URL: https://www.ketorol.ru. 3. Ketorolac: instructions for use. URL: https://www.rlsnet.ru/tn_index_id_1720.htm. 4. Ketorol: instructions for use. URL: https://www.ketorol.ru. 5. Shostak N.A., Pravdyuk N.G., Egorova V.A. Back pain in the elderly - approaches to diagnosis and treatment // Clinician. 2011. No. 3. pp. 72–77. 6. Timofeev A.A., Ushko N.A., Dakal A.V. and others. Comparative characteristics of non-narcotic analgesics used in maxillofacial surgery // Practitioner dentist. 2012. No. 2. P. 48–51. 7. Vertkin A.L., Topolyansky A.V., Vovk E.I. and others. The place of Ketorolac in the treatment of acute pain syndromes at the prehospital stage // Emergency Doctor. 2006. No. 6. P. 1–6. 8. Vertkin A.L., Topolyansky A.V., Vovk E.I. and others. The place of Ketorolac in the treatment of acute pain syndromes at the prehospital stage // Consilium medicum. 2006. T. 8. No. 2. P. 86–90. 9. Jelinek GA Ketorolac versus morphine for severe pain. Ketorolac is more effective, cheaper, and has fewer side effects // Br Med J. 2000. Vol. 321. R. 1236–1237. 10. Forrest JB, Camu F, Greer IA et al. Ketorolac, diclofenac, and ketoprofen are equally safe for pain relief after major surgery // Br J Anaesth. 2002. Vol. 88(2). R. 227–233. 11. Wood VM, Christenson JM, Innes GD et al. The NARC (nonsteroidal anti-inflammatory in renal colic) trial. Single-dose intravenous ketorolac versus titrated intravenous meperidine in acute renal colic: a randomized clinical trial // CJEM. 2000. Vol. 2 (2). R. 83–89. 12. Moeller C., Pawlowski J., Pappas AL et al. The safety and efficacy of intravenous ketorolac in patients undergoing primary endoscopic sinus surgery: a randomized, double-blinded clinical trial // Int Forum Allergy Rhinol. 2012. Vol. 2 (4). R. 342–347. 13. Mireku-Boateng AO Intravenous ketorolac significantly reduces the pain of office transrectal ultrasound and prostate biopsies // Urol Int. 2004. Vol. 73(2). R. 123–124. 14. Bazikyan E.A., Ignatovich V.V. Evaluation of the effectiveness of Ketorol and Nise in the clinical practice of surgical dentistry // Dentistry. 2005. T. 84. No. 3. P. 49–50. 15. Egorova O.A. Efficacy and safety of Ketorol for pain syndrome in an outpatient surgical dentistry clinic // Dentistry. 2009. No. 6. pp. 53–54. 16. Galushko E.A., Zotkin E.G., Salikhov I.G. and others. Clinical effectiveness and tolerability of various NSAIDs for osteoarthritis with severe pain // Attending physician. 2008. No. 4. pp. 82–84. 17. Garkavi A., Silin L., Semevsky A. Relief of acute pain syndrome in patients with pathology of the musculoskeletal system in the early post-traumatic and postoperative periods // Doctor. 2006. No. 13. pp. 40–44. 18. Skvortsov V.V., Tumarenko A.V., Odintsov V.V. and others. Current issues in the diagnosis and treatment of glenohumeral periarthritis // Polyclinic. 2011. No. 2. P. 56–58. 19. Bragina G.I., Vinogradova L.A., Gorshkova Yu.M. and others. Pain syndrome in outpatient practice: Ketorol // Bulletin of Family Medicine. 2006. No. 2. P. 44–47. 20. Vertkin A.L., Prokhorovich E.A., Goruleva E.A. and others. Efficacy and safety of using Ketorol for pain relief at the prehospital stage // Emergency Therapy. 2004. No. 1–2. pp. 16–17. 21. Vertkin A.L., Shamuilova M.M., Naumov A.V. Assessing the effectiveness and safety of the use of non-steroidal anti-inflammatory drugs for pain relief in the practice of an on-duty doctor in a multidisciplinary hospital // Drug supply and pharmacoeconomics. 2011. No. 5. pp. 76–84. 22. Tabeeva G.R. Cervicogenic headache: pathophysiology, clinical picture, approaches to therapy // Neurology, neuropsychiatry, psychosomatics. 2010. No. 2. pp. 19–26. 23. Shavlovskaya O.A. Clinical efficacy and tolerability of Ketorolac in the treatment of pain syndromes // Consilium medicum. 2013. T. 15. No. 2. P. 34–37.
What does the choice depend on?
The doctor determines the form of administration, relying not only on those drugs that are available. He pays attention to the patient’s age, gender, financial capabilities, and even his mood and attitude towards treatment. Children require special attention.
“Choosing the form of a drug is partly a creative process,” says Ekaterina Bokova, a therapist at the 120 to 80 clinic. “There are no ready-made solutions here. But most often we focus on age. If this is a very young baby, then we choose liquid or rectal forms to prevent spitting and choking. This way, the child will receive his dose of the active substance with a greater guarantee. Sometimes you even have to make a choice in favor of an injectable drug. In any case, a child should not be prescribed “adult” pills and divided into parts.”
The wishes of the patient or relatives also matter when choosing the form of the medicine. For older people, it is important to take fewer pills per day, otherwise you can get confused, especially if there are a lot of medications. In such cases, tablet holders or planners help.
“Unfortunately, older people usually insist on prescribing the most affordable drug,” says Ekaterina Bokova, “here, if possible, we will meet them halfway.”
How to choose the right form
Even medications with the same dosage form may differ from each other. For example, capsules and tablets.
“Capsules are more expensive due to the difference in technology,” explains Andrey Besedin. — They hide the unpleasant smell and taste of medications, unlike tablets. The capsules enter the body: the stomach, intestines and, when dissolved, release powder, which is absorbed much more quickly. But there is a factor that many of my patients do not like. The tablets can often be split in half or into quarters and sometimes half the dose is sufficient in an emergency. In the case of a capsule, this will not work, so the choice is made in favor of tablets.”
There are patients who are confident that injections and droppers are much healthier than tablets and specifically insist on this form of treatment. It is believed that in this case the medicine goes directly into the blood and will definitely work. Although this method of administration is more difficult, more painful and most often there is no difference in the result if the same medicine is in the form of tablets or ampoules.
“For example, patients ask for intramuscular or intravenous painkillers for headaches,” says Andrey Besedin. — This type of administration has no advantages compared to oral forms: powders, capsules, tablets, if the patient can take medications by mouth. As a rule, injections are effective if a person has a large loss of fluid or for some reason cannot drink on his own.”
Intravenous and intramuscular delivery methods are more useful in emergency cases of stomach or intestinal disease or in situations where a drug is broken down in the digestive tract, such as heparin or insulin.
Ketorol Insta tablets dispersible in the oral cavity 10 mg No. 10x2
Name
Ketorol insta
Description
Light yellow, round, flat tablets engraved with an “I” on one side and smooth on the other.
Main active ingredient
Ketorolac tromethamine - 10 mg.
Release form
pills
Dosage
10 tablets in a blister made of aluminum/desiccant/aluminum foil, 1 blister in a cardboard box with instructions for use.
special instructions
pharmachologic effect
Non-steroidal anti-inflammatory drugs. ATX code: M01 AB15.
Pharmacodynamics
Ketorolac, being a non-steroidal anti-inflammatory drug, has an analgesic, antipyretic and anti-inflammatory effect. The mechanism of action at the biochemical level is inhibition of the cyclooxygenase enzyme, mainly in peripheral tissues, resulting in inhibition of the biosynthesis of prostaglandins - modulators of pain sensitivity, thermoregulation and inflammation. Ketorolac is a racemic mixture
—
S and
+
P enantiomers, with the analgesic effect due to
—
S shape. The drug does not affect opioid receptors, does not depress respiration, does not inhibit intestinal motility, does not have a sedative or anxiolytic effect, does not cause drug dependence, and does not affect the progression of the disease. Ketorolac inhibits platelet aggregation and increases bleeding time. The functional state of platelets is restored 24-48 hours after discontinuation of the drug.
Pharmacokinetics
Ketorolac tromethamine is rapidly and completely absorbed after oral administration with a peak plasma concentration of 0.87 mcg/ml 50 minutes after a single 10 mg dose. In healthy volunteers, the terminal plasma half-life averages 5.4 hours. In older people (average age 72 years) it is 6.2 hours. More than 99% of ketorolac in blood plasma is protein bound. In humans, after single or multiple doses, the pharmacokinetics of ketorolac is linear. Steady-state plasma levels are achieved after one day when administered 4 times daily. No changes were observed with long-term dosing. After a single intravenous dose, the volume of distribution is 0.25 l/kg, the half-life is 5 hours, and the clearance is 0.55 ml/min/kg. The main route of excretion of ketorolac and its metabolites (conjugates and p-hydroxymetabolites) is urine (91.4%), and the rest is excreted in feces. A diet rich in fat reduces the rate of absorption, but not the volume, while antacids do not affect the absorption of ketorolac.
Indications for use
Ketorol Insta, orally dispersible tablets, 10 mg, is used for the short-term treatment of acute pain (including postoperative pain) of moderate to severe intensity, only as a continuation of previous parenteral (intramuscular or intravenous) therapy in a hospital setting, if necessary. The total duration of parenteral and oral therapy with ketorolac should not exceed 5 days due to the possibility of increasing the frequency and severity of adverse reactions. Before taking Ketorol Ineta, consider the potential benefits and risks and options for using another drug. Use the lowest effective dose for the shortest possible time. Patients should be switched to alternative treatment as quickly as possible.
Directions for use and doses
The duration of the course of use of Ketorol Ineta should not exceed 5 days; long-term use, as well as oral administration at a dose of more than 40 mg per day, is not recommended. To reduce the risk of side effects, it is recommended to use the minimum effective dose for the minimum time required to relieve pain. From 17 to 64 years: 10 mg every 4-6 hours as needed. It is not recommended to use the drug in doses exceeding 40 mg per day. For patients receiving ketorolac parenterally and prescribed oral ketorolac tablets, the total combined daily dose should not exceed 90 mg (60 mg for the elderly, patients with impaired renal function, and patients weighing less than 50 mg), and The dosage of the oral form of the drug should not exceed 40 mg per day. Patients should be switched to oral administration of the drug as early as possible. Elderly patients Elderly patients have a higher risk of developing severe complications, particularly from the digestive tract. During treatment with NSAIDs, the patient's condition should be regularly monitored; a longer interval between doses of the drug is usually recommended, for example, 6-8 hours. Dispersible tablets can be used in patients with swallowing dysfunction. Can be taken without drinking water. The tablet is placed on the tongue, kept in the mouth until it is completely dissolved (do not chew), then swallowed.
Use during pregnancy and lactation
The safety of ketorolac during pregnancy has not been established. Given the known effect of NSAIDs on the cardiovascular system of the fetus (risk of premature closure of the ductus arteriosus), ketorolac is contraindicated during pregnancy, labor and childbirth. The onset of labor may be delayed and the duration prolonged, with an increased tendency for bleeding to occur in both mother and baby. Ketorolac is excreted into breast milk in small quantities, therefore Ketorol Insta is contraindicated during breastfeeding.
Precautionary measures
The maximum duration of use, including the use of parenteral forms, should not exceed 5 days. Gastrointestinal bleeding, ulceration and perforation. Gastrointestinal bleeding, ulceration or perforation, which may be fatal, has been reported with the use of NSAIDs at any time during treatment, with or without warning symptoms or in the case of a history of severe gastrointestinal disorders. The risk of developing severe gastrointestinal bleeding depends on the dosage of the drug. This, in particular, applies to elderly patients who use ketorolac in an average daily dose above 60 mg. For these patients, as well as for patients who are concomitantly using low doses of acetylsalicylic acid or other drugs that may increase gastrointestinal risk, combination treatment with protective agents (eg, misoprostol or proton pump inhibitors) should be considered. Ketorol Ineta should be used with caution in patients receiving concurrent medications that may increase the risk of ulceration or bleeding, such as oral corticosteroids, selective serotonin reuptake inhibitors, or antiplatelet agents such as acetylsalicylic acid. If gastrointestinal bleeding or ulceration occurs in patients receiving Ketorol Ineta, the course of treatment should be discontinued. Respiratory dysfunction. Caution is required when using the drug in patients with bronchial asthma (or with a history of asthma), since NSAIDs have been reported to accelerate the onset of bronchospasm in such patients. Effect on the kidneys. Prostaglandin biosynthesis inhibitors (including NSAIDs) have been reported to have nephrotoxic effects. The drug should be prescribed with caution to patients with impaired renal, cardiac, or liver function, since the use of NSAIDs may lead to deterioration of renal function. Patients with mildly impaired renal function are prescribed lower doses of ketorolac (those that do not exceed 60 mg per day intramuscularly or intravenously), and the renal condition of such patients should be carefully monitored. As with other drugs that inhibit prostaglandin synthesis, increases in serum urea, creatinine, and potassium have been reported during use of ketorolac tromethamine, which may occur after a single dose. Disorders of the cardiovascular system, kidneys and liver. The drug should be used with caution in patients with conditions that lead to a decrease in blood volume and/or renal blood flow, when renal prostaglandins play a supporting role in ensuring renal perfusion. In these patients, renal function should be monitored. The volume reduction should be corrected and serum urea and creatinine levels and the volume of urine excreted carefully monitored until the patient becomes normovolemic. In patients on renal dialysis, the clearance of ketorolac was reduced by approximately half the normal rate, and the terminal half-life was approximately tripled. Patients with impaired liver function due to cirrhosis did not have any clinically significant changes in ketorolac clearance or terminal half-life. Borderline increases in one or more liver function tests may occur. These abnormalities may be temporary, may remain unchanged, or may progress with continued treatment. If clinical signs and symptoms indicate the development of liver disease or if systemic manifestations are observed, Ketorol Ineta should be discontinued. Fluid retention and edema Fluid retention and edema have been reported during the use of ketorolac and should be used with caution in patients with cardiac decompensation, hypertension or similar conditions. Cardiovascular and cerebrovascular effects. There is currently insufficient information to assess such a risk for ketorolac tromethamine. Patients with uncontrolled hypertension, congestive heart failure, diagnosed coronary artery disease, peripheral arterial disease and/or cerebrovascular disease should be under medical supervision. Systemic lupus erythematosus and mixed connective tissue diseases. In patients with systemic lupus erythematosus and various mixed connective tissue diseases, the risk of developing aseptic meningitis increases. Dermatological. Ketorol Ineta should be discontinued at the first signs of a skin rash, damage to the mucous membranes or any other signs of hypersensitivity. Anaphylactic (anaphylactoid) reactions. As with the use of other NSAIDs, anaphylactic (anaphylactoid) reactions (including anaphylaxis, bronchospasm, hyperemia, rash, hypotension, laryngeal edema, Quincke's edema) may occur in patients who have no or no history of hypersensitivity to aspirin, other NSAIDs or ketorolac. This set of symptoms may also occur in individuals with a history of bronchospastic reactivity (eg, asthma) and nasal polyps. Anaphylactoid reactions, such as anaphylaxis, can be fatal. Therefore, ketorolac should not be taken by patients with a history of asthma and patients with complete or partial nasal polyp syndrome, angioedema and bronchospasm. If anaphylactoid reactions occur, seek emergency medical attention. Hematological effects. Patients with bleeding disorders should not be prescribed Ketorol Ineta. Patients receiving anticoagulant therapy may have an increased risk of bleeding if ketorolac is used concomitantly. Patients receiving other drugs that may affect the rate of bleeding control should be carefully monitored when ketorolac is prescribed to them. In controlled clinical trials, the incidence of significant postoperative bleeding was less than 1%. Ketorolac inhibits platelet aggregation and prolongs bleeding time. In patients with normal bleeding times, the duration of bleeding increased, but did not exceed the normal range of 2-11 minutes. In contrast to the long-term effects resulting from the use of acetylsalicylic acid, platelet function returns to normal within 24-48 hours after discontinuation of ketorolac. Ketorolac should not be prescribed to patients who have undergone surgery with a high risk of bleeding or incomplete control of bleeding. Caution should be used if mandatory bleeding control is critical. Ketorol Ineta is not an anesthetic and does not have sedative or anxiolytic properties; therefore, it is not recommended as a pre-operative sedative to maintain anesthesia.
Interaction with other drugs
Due to the possibility of side effects, ketorolac should not be prescribed with other NSAIDs, including selective cyclooxygenase-2 inhibitors, or in patients receiving acetylsalicylic acid, warfarin, lithium, probenecid, cyclosporine. NSAIDs should not be prescribed within 8-12 days after using mifepristone, since NSAIDs may weaken the effect of mifepristone. Medicines in combination with ketorolac should be prescribed with caution. In healthy normovolemic individuals, ketorolac reduces the diuretic effect of furosemide by approximately 20%; therefore, the drug is prescribed with particular caution to patients with cardiac decompensation. NSAIDs may worsen heart failure, reduce glomerular filtration rate, and increase plasma levels of cardiac glycosides when coadministered with cardiac glycosides. Ketorolac and other non-steroidal anti-inflammatory drugs may weaken the effect of antihypertensive drugs. In the case of simultaneous use of ketorolac with ACE inhibitors, there is an increased risk of renal dysfunction, especially in patients with a reduced blood volume in the body. There is a possible risk of nephrotoxicity if NSAIDs are prescribed with tacrolimus. Co-administration with diuretics may lead to a weakening of the diuretic effect and an increased risk of NSAID nephrotoxicity. As with all NSAIDs, caution is required when coadministering corticosteroids due to the increased risk of gastrointestinal ulceration or bleeding. There is an increased risk of gastrointestinal bleeding if NSAIDs are prescribed in combination with antiplatelet agents and selective serotonin reuptake inhibitors. Caution is advised if methotrexate is coadministered as some prostaglandin synthesis inhibitors have been reported to reduce the clearance of methotrexate and therefore possibly increase its toxicity. Patients taking NSAIDs and quinolones may have an increased risk of developing seizures. Concomitant use of NSAIDs with zidovudine leads to an increased risk of hematological toxicity. There is an increased risk of hemarthrosis and hematoma in HIV-infected people who have hemophilia and who are treated with both zidovudine and ibuprofen. The following drugs are unlikely to interact with ketorolac. Ketorolac did not affect the binding of digoxin to plasma protein. In vitro studies indicate that at therapeutic salicylate concentrations (300 mcg/mL) and higher, ketorolac binding was reduced by approximately 99.2% to 97.5%. Therapeutic concentrations of digoxin, warfarin, paracetamol, phenytoin and tolbutamide did not affect the binding of ketorolac to plasma protein. Because ketorolac is a highly active drug and its available plasma concentration is low, it is not expected to significantly replace other drugs that bind to plasma proteins. There is no evidence from animal or human studies that ketorolac tromethamine induces or inhibits liver enzymes that are capable of metabolizing it or other drugs. Therefore, ketorolac is not expected to be metabolized by it or other drugs. Therefore, ketorolac is not expected to alter the pharmacokinetics of other drugs.
Contraindications
Hypersensitivity to ketorolac or any component of the drug; patients with an active peptic ulcer, with recent gastrointestinal bleeding or perforation, with a history of peptic ulcer disease or gastrointestinal bleeding; bronchial asthma, rhinitis, angioedema or urticaria caused by the use of acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (due to the possibility of severe anaphylactic reactions); do not use as an analgesic before and during surgery; complete or partial nasal polyp syndrome, angioedema or bronchospasm; do not use in patients who have had surgery with a high risk of hemorrhage or incomplete bleeding control and in patients who receive anticoagulants, including low doses of heparin (2500-5000 units every 12 hours); hepatic or moderate to severe renal failure (serum creatinine concentration more than 160 µmol/l; suspected or confirmed cerebrovascular bleeding, bleeding diathesis, including coagulation disorders and a high risk of bleeding; concomitant treatment with other non-steroidal anti-inflammatory drugs (NSAIDs) (including selective inhibitors cyclooxygenase), acetylsalicylic acid, warfarin, pentoxifylline, probenecid or lithium salts; hypovolemia, dehydration; pregnancy, labor, childbirth and breastfeeding; children under 16 years of age; erosive and ulcerative lesions and inflammatory diseases of the oral cavity.
Compound
Active ingredient: ketorolac tromethamine – 10 mg; excipients - microcrystalline cellulose, hydrated colloidal silicon dioxide; antioxidant butylated hydroxyanisole, mannitol crospovidone, sucralose, mint flavor, quinoline yellow dye (E104), magnesium stearate.
Overdose
Symptoms: headache, nausea, vomiting, epigastric pain, gastrointestinal bleeding; rarely - diarrhea, disorientation, agitation, coma, drowsiness, dizziness, ringing in the ears, loss of consciousness, sometimes convulsions. In cases of severe poisoning, acute renal failure and liver damage are possible. Anaphylactoid reactions have been observed after therapeutic use of NSAIDs, which may occur after overdose. Treatment: gastric lavage, use of activated carbon. It is necessary to ensure sufficient diuresis. Kidney and liver function should be carefully monitored. Patients should be monitored for at least 4 hours after ingestion of a potentially toxic amount. Frequent or prolonged seizures should be treated with intravenous diazepam. Other measures may be prescribed depending on the patient's clinical condition. Therapy is symptomatic.
Side effect
From the digestive tract: peptic ulcer, perforation or gastrointestinal bleeding, sometimes fatal (especially in the elderly), nausea, dyspepsia, gastrointestinal pain, abdominal discomfort, hematemesis, gastritis, esophagitis, diarrhea, belching, constipation, flatulence, feeling of fullness in the stomach, melena, rectal bleeding, ulcerative stomatitis, vomiting, hemorrhage, perforation, pancreatitis, exacerbation of colitis and Crohn's disease. From the central nervous system: anxiety, blurred vision, optic neuritis, drowsiness, dizziness, increased sweating, dry mouth, nervousness, paresthesia, functional disorders, depression, euphoria, convulsions, inability to concentrate, insomnia, increased fatigue, agitation, vertigo, impaired taste and vision, myalgia, unusual dreams, confusion, hallucinations, hyperkinesia, hearing loss, tinnitus, psychotic reactions, thinking disorders. Infectious diseases: aseptic meningitis (especially in patients with autoimmune diseases such as systemic lupus erythematosus, mixed connective tissue disease), stiff neck, headache, nausea, vomiting, fever, confusion. Metabolism and nutrition: anorexia, hyponatremia, hyperkalemia. From the urinary system, increased urinary frequency, oliguria, acute renal failure, hemolytic uremic syndrome, flank pain (with/without hematuria), increased serum urea and creatinine, interstitial nephritis, urinary retention, nephrotic syndrome, infertility, renal failure. From the liver: impaired liver function, hepatitis, jaundice and liver failure, increased functional tests. From the cardiovascular system: flushing of the face, bradycardia, pallor, hypertension, hypotension, palpitation, chest pain, edema, heart failure. Data from clinical and epidemiological studies indicate that the use of certain NSAIDs, especially in high doses and for long periods of time, may be associated with an increased risk of arterial thromboembolic complications (myocardial infarction or stroke). From the respiratory system: nosebleeds, shortness of breath, asthma, pulmonary edema. From the blood system: purpura, thrombocytopenia, neutropenia, agranulocytosis, aplastic and hemolytic anemia. Skin: itching, urticaria, photosensitivity of the skin, Lyell's syndrome, bullous reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis (very rare), exfoliative dermatitis, maculopapular rashes. Effect on reproductive function: the use of ketorolac, like any drug that inhibits the synthesis of cyclooxygenase/prostaglandin, can cause infertility. Hypersensitivity: Hypersensitivity reactions have been reported, which include nonspecific allergic reactions and anaphylaxis, respiratory tract reactivity including asthma, worsening asthma, bronchospasm, laryngeal edema or shortness of breath, and a variety of skin disorders that include various types of rashes, itching , urticaria, purpura, angioedema, and in isolated cases, exfoliative and bullous dermatitis (including epidermal necrolysis and erythema multiforme). Such reactions may occur in patients without or with known hypersensitivity to ketorolac or other non-steroidal anti-inflammatory drugs. They may also occur in individuals with a history of angioedema, bronchospastic reactivity (eg, asthma, and nasal polyps). Anaphylactoid reactions, such as anaphylaxis, can be fatal. Others: postoperative bleeding from a wound, hematoma, prolongation of bleeding, asthenia, edema, weight gain, increased body temperature, excessive thirst, fatigue, malaise, fever, chest pain. To prevent possible side effects, one should strive to use the minimum effective doses of the drug, strictly adhere to the established dosages and administration regimens, take into account the patient’s condition (age, renal function, state of the gastrointestinal tract, water-electrolyte metabolism and hemostatic system), as well as possible drug interactions with combination therapy.
Storage conditions
Store at a temperature not exceeding 25°C. Keep out of the reach of children.
Buy Ketorol Insta tablets dispersible in the oral cavity 10 mg No. 10x2 in the pharmacy
Price for Ketorol Insta tablets dispersible in the oral cavity 10 mg No. 10x2
Instructions for use for Ketorol Insta tablets dispersible in the oral cavity 10 mg No. 10x2
